Somatostatin receptors as tools for diagnosis and therapy: Molecular aspects

Best Practice and Research: Clinical Gastroenterology

Volumn 19, Issue 4 SPEC. ISS., 2005, Pages 535-551

  Guillermet Guibert, Julie ^a   Lahlou, Hicham ^a   Pyronnet, Stéphane ^a   Bousquet, Corinne ^a   Susini, Christiane ^a  

^a INSERM   (France)

Author keywords

Endocrine tumour; Receptors; Signal transduction; Somatostatin

Indexed keywords

2 PYRROLINODOXORUBICIN; ANGIOPEPTIN; CALCINEURIN; CALCIUM ION; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR 2; G PROTEIN COUPLED RECEPTOR; GASTRIN; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; NEUROPEPTIDE; NITRIC OXIDE; OCTREOTIDE; PASIREOTIDE; PHOSPHATASE; POTASSIUM ION; PROTEIN BAX; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SODIUM ION; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; STAT5B PROTEIN; UNINDEXED DRUG; VAPREOTIDE; VASCULOTROPIN; YTTRIUM 90; DIAGNOSTIC AGENT; DRUG DERIVATIVE; INDIUM; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PENTETREOTIDE; VASCULOTROPIN A;

ACROMEGALY; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CANCER DIAGNOSIS; CANCER THERAPY; CARCINOID; CELL PROLIFERATION; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; EXOCRINE SECRETION; HORMONE RELEASE; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; MOLECULAR MECHANICS; NEUROENDOCRINE TUMOR; NONHUMAN; OLIGOMERIZATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR CELL; ANGIOGENESIS; GASTROINTESTINAL TUMOR; METABOLISM; PANCREAS TUMOR; PHYSIOLOGY;

GASTROINTESTINAL NEOPLASMS; HUMANS; INDIUM RADIOISOTOPES; MAP KINASE KINASE 2; NEOVASCULARIZATION, PHYSIOLOGIC; PANCREATIC NEOPLASMS; RECEPTORS, SOMATOSTATIN; SIGNAL TRANSDUCTION; SOMATOSTATIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 26844529748     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2005.03.007     Document Type: Review

References (97)

1. V.A. Dalm P.M. Van Hagen R.R. de Krijger et al. Distribution pattern of somatostatin and cortistatin mRNA in human central and peripheral tissues Clin Endocrinol (Oxf) 60 2004 625-629
2. Y.C. Patel Somatostatin and its receptor family Front Neuroendocrinol 20 1999 157-198
3. G. Olias C. Viollet H. Kusserow et al. Regulation and function of somatostatin receptors J Neurochem 89 2004 1057-1091
4. N. Robas E. Mead & M. Fidock MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion J Biol Chem 278 2003 44400-44404
5. W. Meyerhof The elucidation of somatostatin receptor functions: A current view Rev Physiol Biochem Pharmacol 133 1998 55-108
6. G. Weckbecker I. Lewis R. Albert et al. Opportunities in somatostatin research: Biological, chemical and therapeutic aspects Nat Rev Drug Discov 2 2003 999-1017
7. M.Z. Strowski R.M. Parmar A.D. Blake et al. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: An in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice Endocrinology 141 2000 111-117
8. H.J. Kreienkamp H.H. Honck & D. Richter Coupling of rat somatostatin receptor subtypes to a G-protein gated inwardly rectifying potassium channel (GIRK1) FEBS Lett 419 1997 92-94
9. M. Tallent G. Liapakis O.C. AM et al. Somatostatin receptor subtypes SSTR2 and SSTR5 couple negatively to an l -type Ca2+ current in the pituitary cell line AtT-20 Neuroscience 71 1996 1073-1081
10. D. Roosterman G. Glassmeier H. Baumeister et al. A somatostatin receptor 1 selective ligand inhibits Ca2+ currents in rat insulinoma 1046-38 cells FEBS Lett 425 1998 137-140
11. E. Renstrom W.G. Ding K. Bokvist et al. Neurotransmitter-induced inhibition of exocytosis in insulin-secreting beta cells by activation of calcineurin Neuron 17 1996 513-522
12. D. Cervia S. Fiorini B. Pavan et al. Somatostatin (SRIF) modulates distinct signaling pathways in rat pituitary tumour cells; negative coupling of SRIF receptor subtypes 1 and 2 to arachidonic acid release Naunyn Schmiedebergs Arch Pharmacol 365 2002 200-209
13. A.V. Schally A.M. Comaru-Schally A. Nagy et al. Hypothalamic hormones and cancer Front Neuroendocrinol 22 2001 248-291
14. A.V. Schally K. Szepeshazi A. Nagy et al. New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogues Cell Mol Life Sci 61 2004 1042-1068
15. G. Weckbecker F. Raulf B. Stolz et al. Somatostatin analogues for diagnosis and treatment of cancer Pharmacol Ther 60 1993 245-264
16. R.D. Murray K. Kim S.G. Ren et al. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis J Clin Invest 114 2004 349-356
17. E.A. Woltering J.C. Watson R.C. Alperin-Lea et al. Somatostatin analogues: Angiogenesis inhibitors with novel mechanisms of action Invest New Drugs 15 1997 77-86
18. J.C. Reubi B. Waser J.C. Schaer et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands Eur J Nucl Med 28 2001 836-846
19. J.C. Watson D.A. Balster B.M. Gebhardt et al. Growing vascular endothelial cells express somatostatin subtype 2 receptors Br J Cancer 85 2001 266-272
20. E.A. Woltering Development of targeted somatostatin-based antiangiogenic therapy: A review and future perspectives Cancer Biother Radiopharm 18 2003 601-609
21. R.L. Adams I.P. Adams S.W. Lindow et al. Inhibition of endothelial proliferation by the somatostatin analogue SOM230 Clin Endocrinol (Oxf) 61 2004 431-436
22. T. Florio M. Morini V. Villa et al. Somatostatin inhibits tumour angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities Endocrinology 144 2003 1574-1584
23. S. Arena A. Pattarozzi A. Corsaro et al. Somatostatin receptor subtype-dependent regulation of nitric oxide release: Involvement of different intracellular pathways Mol Endocrinol 19 2005 255-267
24. N. Ferrara Molecular and biological properties of vascular endothelial growth factor J Mol Med 77 1999 527-543
25. R. Mentlein O. Eichler F. Forstreuter et al. Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells Int J Cancer 92 2001 545-550
26. J.W. Sall D.D. Klisovic M.S. O'Dorisio et al. Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells Exp Eye Res 79 2004 465-476
27. S. Cascinu E. Del Ferro M. Ligi et al. Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients Cancer Invest 19 2001 8-12
28. A. Albini T. Florio D. Giunciuglio et al. Somatostatin controls Kaposi's sarcoma tumour growth through inhibition of angiogenesis FASEB J 13 1999 647-655
29. M. Le Romancer F. Reyl-Desmars S. Levasseur et al. The 86-kDa subunit of autoantigen Ku is a somatostatin receptor regulating protein phosphatase-2A activity J Biol Chem 269 1994 17464-17468
30. J. Held-Feindt F. Forstreuter T. Pufe et al. Influence of the somatostatin receptor sst2 on growth factor signal cascades in human glioma cells Brain Res Mol Brain Res 87 2001 12-21
31. F. Lopez J.P. Esteve L. Buscail et al. The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling J Biol Chem 272 1997 24448-24454
32. C.B. Srikant & S.H. Shen Octapeptide somatostatin analogue SMS 201-995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells Endocrinology 137 1996 3461-3468
33. S.P. Oomen A.C. Ward L.J. Hofland et al. Somatostatin modulates G-CSF-induced but not interleukin-3-induced proliferative responses in myeloid 32D cells via activation of somatostatin receptor subtype 2 Hematol J 2 2001 322-329
34. P.D. Zapata R.M. Ropero A.M. Valencia et al. Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1 J Clin Endocrinol Metab 87 2002 915-926
35. P. Pages N. Benali N. Saint-Laurent et al. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of Shp-1 J Biol Chem 274 1999 15186-15193
36. T. Florio S. Arena S. Thellung et al. The activation of the phosphotyrosine phosphatase eta (r-PTP eta) is responsible for the somatostatin inhibition of PC Cl3 thyroid cell proliferation Mol Endocrinol 15 2001 1838-1852
37. K.S. Smalley W. Feniuk L.A. Sellers et al. The pivotal role of phosphoinositide-3 kinase in the human somatostatin sst(4) receptor-mediated stimulation of p44/p42 mitogen-activated protein kinase and extracellular acidification Biochem Biophys Res Commun 263 1999 239-243
38. M.G. Cattaneo J.E. Taylor M.D. Culler et al. Selective stimulation of somatostatin receptor subtypes: Differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells FEBS Lett 481 2000 271-276
39. P. Cordelier J.P. Esteve C. Bousquet et al. Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5 Proc Natl Acad Sci USA 94 1997 9343-9348
40. T. Florio H. Yao K.D. Carey et al. Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1) Mol Endocrinol 13 1999 24-37
41. H. Bito M. Mori C. Sakanaka et al. Functional coupling of SSTR4, a major hippocampal somatostatin receptor, to adenylate cyclase inhibition, arachidonate release and activation of the mitogen-activated protein kinase cascade J Biol Chem 269 1994 12722-12730
42. H. Lahlou N. Saint-Laurent J.P. Esteve et al. SST2 somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation J Biol Chem 278 2003 39356-39371
43. F. Alderton P.P. Humphrey & L.A. Sellers High-intensity p38 kinase activity is critical for p21(cip1) induction and the antiproliferative function of G(i) protein-coupled receptors Mol Pharmacol 59 2001 1119-1128
44. G. Ferjoux F. Lopez J.P. Esteve et al. Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation Mol Biol Cell 14 2003 3911-3928
45. H. Lahlou M. Fanjul L. Pradayrol et al. Restoration of functional gap junctions through IRES-dependent synthesis of endogenous connexins in density-inhibited cancer cells Mol Cell Biol 2005 (in press)
46. R. Teijeiro R. Rios J.A. Costoya et al. Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53 Cell Physiol Biochem 12 2002 31-38
47. K. Sharma & C.B. Srikant Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells Int J Cancer 76 1998 259-266
48. D. Lattuada C. Casnici A. Venuto et al. The apoptotic effect of somatostatin analogue SMS 201-995 on human lymphocytes J Neuroimmunol 133 2002 211-216
49. K. Sharma Y.C. Patel & C.B. Srikant Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3 Mol Endocrinol 10 1996 1688-1696
50. J. Guillermet N. Saint-Laurent P. Rochaix et al. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis Proc Natl Acad Sci USA 100 2003 155-160
51. M. Rocheville D.C. Lange U. Kumar et al. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers J Biol Chem 275 2000 7862-7869
52. R.C. Patel U. Kumar D.C. Lamb et al. Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells Proc Natl Acad Sci USA 99 2002 3294-3299
53. M. Pfeiffer T. Koch H. Schroder et al. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A) J Biol Chem 276 2001 14027-14036
54. M. Pfeiffer T. Koch H. Schroder et al. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization J Biol Chem 277 2002 19762-19772
55. M. Rocheville D.C. Lange U. Kumar et al.Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity Science 288 2000 154-157
56. A. Saveanu E. Lavaque G. Gunz et al. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells J Clin Endocrinol Metab 87 2002 5545-5552
57. Y.C. Patel Molecular pharmacology of somatostatin receptor subtypes. Molecular pharmacology of somatostatin receptor subtypes J Endocrinol Invest 20 1997 348-367
58. J.C. Reubi J.C. Schaer B. Waser et al. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumours using in situ hybridization Cancer Res 54 1994 3455-3459
59. H. Kulaksiz R. Eissele D. Rossler et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies Gut 50 2002 52-60
60. E.T. Janson M. Stridsberg A. Gobl et al. Determination of somatostatin receptor subtype 2 in carcinoid tumours by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies Cancer Res 58 1998 2375-2378
61. L.J. Hofland Q. Liu P.M. Van Koetsveld et al. Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumours J Clin Endocrinol Metab 84 1999 775-780
62. N. Kimura M. Pilichowska F. Date et al. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumours Clin Cancer Res 5 1999 3483-3487
63. J.C. Reubi & B. Waser Concomitant expression of several peptide receptors in neuroendocrine tumours: Molecular basis for in vivo multireceptor tumour targeting Eur J Nucl Med Mol Imaging 30 2003 781-793
64. M. Papotti M. Bongiovanni M. Volante et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumours. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis Virchows Arch 440 2002 461-475
65. Y. Oda Y. Tanaka T. Naruse et al. Expression of somatostatin receptor and effects of somatostatin analogue on pancreatic endocrine tumours Surg Today 32 2002 690-694
66. M.L. Fjallskog E. Ludvigsen M. Stridsberg et al. Expression of somatostatin receptor subtypes 1 to 5 in tumour tissue and intratumoural vessels in malignant endocrine pancreatic tumours Med Oncol 20 2003 59-67
67. J. Mundschenk N. Unger S. Schulz et al. Somatostatin receptor subtypes in human pheochromocytoma: Subcellular expression pattern and functional relevance for octreotide scintigraphy J Clin Endocrinol Metab 88 2003 5150-5157
68. Q. Liu J.C. Reubi Y. Wang et al. In vivo phosphorylation of the somatostatin 2A receptor in human tumours J Clin Endocrinol Metab 88 2003 6073-6079
69. E.T. Janson & K. Oberg Neuroendocrine tumours-somatostatin receptor expression and somatostatin analogue treatment Cancer Chemother Biol Response Modif 21 2003 535-546
70. M. di Bartolomeo E. Bajetta R. Buzzoni et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumours. A study by the Italian Trials in Medical Oncology Group Cancer 77 1996 402-408
71. R. Arnold B. Simon & M. Wied Treatment of neuroendocrine GEP tumours with somatostatin analogues: A review Digestion 62 2000 84-91
72. S. Ricci A. Antonuzzo L. Galli et al. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumours pretreated with lanreotide Ann Oncol 11 2000 1127-1130
73. H. Shojamanesh F. Gibril A. Louie et al. Prospective study of the antitumour efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma Cancer 94 2002 331-343
74. K. Oberg Future aspects of somatostatin-receptor-mediated therapy Neuroendocrinology 80 supplement 1 2004 57-61
75. S.V. Welin E.T. Janson A. Sundin et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours Eur J Endocrinol 151 2004 107-112
76. L.J. Hofland & S.W. Lamberts The pathophysiological consequences of somatostatin receptor internalization and resistance Endocr Rev 24 2003 28-47
77. C.M. Tan A.E. Brady H.H. Nickols et al. Membrane trafficking of G protein-coupled receptors Annu Rev Pharmacol Toxicol 44 2004 559-609
78. P. Sarret M.J. Esdaile P.S. McPherson et al. Role of amphiphysin II in somatostatin receptor trafficking in neuroendocrine cells J Biol Chem 279 2004 8029-8037
79. G. Tulipano R. Stumm M. Pfeiffer et al. Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes J Biol Chem 279 2004 21374-21382
80. L.J. Hofland S.W. Lamberts P.M. van Hagen et al. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs J Nucl Med 44 2003 1315-1321
81. E.P. Krenning D.J. Kwekkeboom W.H. Bakker et al. Somatostatin receptor scintigraphy with [111In-DTPA- d -Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients Eur J Nucl Med 20 1993 716-731
82. W.W. de Herder & S.W. Lamberts Somatostatin analogue therapy in treatment of gastrointestinal disorders and tumours Endocrine 20 2003 285-290
83. L.J. Hofland W.A. Breeman E.P. Krenning et al. Internalization of [DOTA degrees, 125I-Tyr3]Octreotide by somatostatin receptor-positive cells in vitro and in vivo: Implications for somatostatin receptor-targeted radio-guided surgery Proc Assoc Am Physicians 111 1999 63-69
84. D.J. Kwekkeboom W.H. Bakker B.L. Kam et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate Eur J Nucl Med Mol Imaging 30 2003 417-422
85. I. Virgolini P. Patri C. Novotny et al. Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy Ann Oncol 12 supplement 2 2001 S41-S45
86. I. Virgolini K. Britton J. Buscombe et al. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial Semin Nucl Med 32 2002 148-155
87. A.V. Schally & A. Nagy Chemotherapy targeted to cancers through tumoural hormone receptors Trends Endocrinol Metab 15 2004 300-310
88. K. Szepeshazi A.V. Schally A. Nagy et al. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogues of somatostatin and bombesin on human gastric carcinomas Cancer 98 2003 1401-1410
89. H. Kiaris A.V. Schally A. Nagy et al. A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice Eur J Cancer 37 2001 620-628
90. D.J. Buchsbaum Imaging and therapy of tumours induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs Semin Nucl Med 34 2004 32-46
91. N. Vaysse H. Lahlou G. Ferjoux et al. Novel therapeutic targets for somatostatin in inflammatory chronic diseases Curr Med Chem Anti-inflamm Anti-allergy Agents 4 2005 91-104
92. C. Bruns I. Lewis U. Briner et al. SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile Eur J Endocrinol 146 2002 707-716
93. R.D. Murray K. Kim S.G. Ren et al. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion J Clin Endocrinol Metab 89 2004 3027-3032
94. J. van der Hoek W.W. de Herder R.A. Feelders et al. A single-dose comparison of the acute effects between the new somatostatin analogue SOM230 and octreotide in acromegalic patients J Clin Endocrinol Metab 89 2004 638-645
95. L.J. Hofland J. van der Hoek P.M. van Koetsveld et al. The novel somatostatin analogue SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro J Clin Endocrinol Metab 89 2004 1577-1585
96. M. Afargan E.T. Janson G. Gelerman et al. Novel long-acting somatostatin analogue with endocrine selectivity: Potent suppression of growth hormone but not of insulin Endocrinology 142 2001 477-486
97. I. Shimon T. Rubinek M. Hadani et al. PTR-3173 (somatoprim), a novel somatostatin analogue with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion J Endocrinol Invest 27 2004 721-727